Archived explainer. For the current picture see today's SLS page.
Why Is SELLAS LIFE SCIENCES (SLS) Stock Up Today?
By the Top Tier Newswire AI Desk · November 18, 2026 at 11:28 AM ET · reviewed against 31 wire stories
SELLAS LIFE SCIENCES (SLS) is up +7.81% in the latest session. Our newswire has captured 31 stories on SLS across 13 sources in the last 36 hours, with AI sentiment reading bullish (avg 60/100).
Public view, delayed 4h. Every headline, price and sentiment read below — and this write-up itself — reaches Pro subscribers live. Public readers see it once it clears the delay.
Sellas Life Sciences (SLS) shares rose 7.81% to $20.65, driven by positive topline results from its pivotal Phase 3 REGAL trial for galinpepimut-s in acute myeloid leukemia. The stock rebounded sharply after opening lower on news of a new equity offering.
What Happened
The company announced the initiation of a public offering to sell $150 million in common stock on November 17, 2026. This capital raise followed the release of positive data from the REGAL trial, which demonstrated that the experimental cancer vaccine extended survival in patients with acute myeloid leukemia. The stock initially gapped down 5.1% to open at $18.18, reflecting a reaction to the dilution news, before reversing course to close at $20.65. The move places the stock near the top of its 52-week range, which spans from $1.39 to $24.89.
What The Data Shows
Trading volume reached 15.3 million shares, which is 2.3 times the three-month daily average. The session high was $21.16 at 9:30 AM ET, while the low was $17.22 at 9:40 AM ET. Over the last eight sessions, the stock has climbed 127.4%, moving from $8.42 to the prior close of $19.15. Unusual options activity included 12 notable prints, with call premium totaling $18.3 million compared to $8.0 million in put premium. The largest single print was $4.2 million. The company has a market cap of $1.5 billion and remains unprofitable with a trailing twelve-month EPS of -0.20. Its beta is 2.70. Retail traders on r/wallstreetbets expressed gratitude for the biotech rally, while social media chatter remained sparse with only one post in seven days.
What To Watch
The stock printed a fresh 52-week high and ten fresh 52-week lows on November 18, 2026. Investors will monitor how the market absorbs the $150 million capital raise and whether the strong trial results sustain the recent upward momentum.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.
SLS · Nov 18 session (5-min) · -6.42% vs prior close · updated 8:53 PM ETAI sentiment, last 36h · averaged over 31 stories · 60/100 bullish
The headlines behind the move
Story flow · 8 stories on the wire, last 36h · hover or tap a dot for the headline
2d agoStocktwits NewsBULLISH 58General
SLS And IBRX Share 3 Institutional Backers With Big Pharma Giants — As Stanley Druckenmiller Makes Bold Prediction: ‘We’re Gonna Beat Cancer’
New York’s pension fund held $1.42 billion in the three pharma giants versus just under $2 million in SLS and IBRX.
2d agoStocktwits NewsBULLISH 74General
SLS Joins MRNA And ANL In Biotech’s Top 3 This Year — Here’s How A Late-2025 Bet Could Grow 10x From Here
A $1,000 investment in SLS at the end of 2025 was worth about $5,080 at Tuesday’s close.
2d agoMarketWatchBEARISH 28General
SELLAS Life Sciences Shares Down in Late Market After Public Offering News
2d agoSeeking AlphaBULLISH 74Product/PR
SELLAS Life Sciences Group, Inc. (SLS) Discusses Positive Phase III REGAL Trial Results for Galinpepimut-S in Acute Myeloid Leukemia Prepared Remarks Transcript
SELLAS Life Sciences Group, Inc. (SLS) Discusses Positive Phase III REGAL Trial Results for Galinpepimut-S in Acute Myeloid Leukemia November 17, 2026 7:45...
2d agoGuruFocusBEARISH 26General
SELLAS Life Sciences Group (SLS) Launches $150M Stock Offering Amid Biotech Growth Prospects
On November 17, 2026, SELLAS Life Sciences Group Inc (NASDAQ: SLS) announced the initiation of a public offering to sell $150 million in common stock, with an u
2d agoInvesting.com MarketsBEARISH 26General
Sellas Life Sciences stock falls on $150M stock offering
Sellas Life Sciences stock falls on $150M stock offering
2d agoInvesting.com MarketsNEUTRAL 50General
After-Hours Movers: NVDA, CRWV, NBIS, AAOI, SLS
After-Hours Movers: NVDA, CRWV, NBIS, AAOI, SLS
2d agoThe FlyBEARISH 26General
Sellas Life Sciences announces $150M common stock offering
Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →